Cardiff Oncology, Inc.
CRDFCardiff Oncology, Inc. in brief
Cardiff Oncology, Inc. is a listed company in the Biotechnology industry, based in San Diego, California, USA. Its market value was $71 M on 30 October 2026, which makes it the 20,040th largest listed company in the world and the 3,703rd largest in the USA on this site. In the year to December 2025 it had sales of $1 M and a net loss of $46 M. Mani Mohindru is its chief executive. Its shares trade under the symbol CRDF (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Cardiff Oncology, Inc.
Trovagene changed the name of company to Cardiff Oncology. Cardiff Oncology is clinical-state biotechnology company with headquarters is in USA.
Cardiff Oncology is a clinical-stage company with the singular mission of developing new treatment options for cancer patients. Their goal is to overcome resistance, extend duration of response and increase overall survival.
Cardiff Oncology, Inc. timeline
- 2003
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2004
- ✎Renamed Xenomics IncFormerly Used Kar Parts Inc.
- 2009
- ✎Renamed TrovaGene Inc.Formerly Xenomics Inc.
- 2020
- ✎Renamed Cardiff Oncology, Inc.Formerly TrovaGene Inc..
- 2024
- 💰Record revenue of $1 millionFY2024, the highest of the 8 years on record.
Events of Cardiff Oncology, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,672 (Jan 2020) · #2,632 (Jan 2021) · #3,588 (Jan 2022) · #4,707 (Dec 2022) · #4,489 (Jul 2023) · #3,884 (Jan 2024) · #1,859 (Mar 2026) · #3,579 (Aug 2026) · #3,624 (Oct 2026) · #3,707 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 128.7×
- Price / book
- 1.6×
- Free cash flow yield
- -53.6%
- Net margin (TTM)
- -6845.5%
- Operating margin
- -8298.3%
- Return on equity
- -82.9%
- Liabilities / assets
- 26.7%
- Net debt
- $-8M
- Revenue growth
- -13.2%
- R&D / revenue
- 5988.1%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $1M | -13.2% | $-49M | $-46M | -7771.2% |
| Dec 2024 | $1M | +38.8% | $-49M | $-45M | -6680.9% |
| Dec 2023 | $0M | +25.6% | $-45M | $-41M | -8457.1% |
| Dec 2022 | $0M | +8.3% | $-40M | $-39M | -9923.1% |
| Dec 2021 | $0M | -2.7% | $-29M | $-28M | -7858.3% |
| Dec 2020 | $0M | +54.2% | $-19M | $-19M | -5218.9% |
| Dec 2019 | $0M | -36.8% | $-17M | $-16M | -6837.5% |
| Dec 2018 | $0M | — | $-17M | $-16M | -4331.6% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-38M | $0M | $-38M | $-0.69 | — |
| Dec 2024 | $-38M | $0M | $-38M | $-0.95 | — |
| Dec 2023 | $-31M | $1M | $-31M | $-0.93 | — |
| Dec 2022 | $-34M | $1M | $-35M | $-0.89 | — |
| Dec 2021 | $-23M | $0M | $-23M | $-0.73 | — |
| Dec 2020 | $-16M | $0M | $-17M | $-1.08 | — |
| Dec 2019 | $-13M | $0M | $-13M | $-2.80 | — |
| Dec 2018 | $-13M | $0M | $-13M | $-8.26 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $0M (+41.7% on a year earlier), net income $-9M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 20268-KCurrent reportResults of operations
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Oct 27, 20268-KCurrent reportDirectors or officers changed · Bylaws amended · Regulation FD disclosure
- Oct 22, 20268-KCurrent reportShareholder vote
- Sep 14, 20268-KCurrent reportMaterial agreement · Regulation FD disclosure
- Aug 26, 2026DEF 14AProxy statement
- Aug 11, 20268-KCurrent reportResults of operations
- Aug 11, 202610-QQuarterly report · period to Jun 2026
- Jul 16, 20268-KCurrent reportMaterial agreement · Other events
- Jun 11, 20268-KCurrent reportShareholder vote
- Jun 3, 20268-KCurrent reportRegulation FD disclosure
- May 29, 20268-KCurrent reportMaterial agreement
Official filings of Cardiff Oncology, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $1 M
- Operating income
- $-49 M
- Net income
- $-46 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $62 M
- Total liabilities
- $17 M
- Total equity
- $45 M
As of December-2025
Top 75 institutional investors in Cardiff Oncology, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Laurion Capital Management LP | 3,098,299 | 0 (0.00%) | 3.98% | $4 M | Oct 30, 2026 |
| 2 | Vanguard Capital Management LLC | 2,867,865 | -27,727 (-0.96%) | 3.69% | $3 M | Nov 13, 2026 |
| 3 | Pfizer Inc | 2,411,575 | 0 (0.00%) | 3.10% | $3 M | Nov 12, 2026 |
| 4 | Franklin Templeton Inc | 1,205,803 | 0 (0.00%) | 1.55% | $1 M | Nov 12, 2026 |
| 5 | BlackRock, Inc. | 935,893 | -36,980 (-3.80%) | 1.20% | $1 M | Nov 13, 2026 |
| 6 | Blair William & Co/il | 916,975 | +4,462 (+0.49%) | 1.18% | $1 M | Nov 10, 2026 |
| 7 | Geode Capital Management, LLC | 839,868 | +19,806 (+2.42%) | 1.08% | $1 M | Nov 6, 2026 |
| 8 | GoalVest Advisory LLC | 687,285 | New | 0.88% | $1 M | Oct 2, 2026 |
| 9 | Gsa Capital Partners LLP | 537,602 | +364,328 (+210.26%) | 0.69% | $1 M | Nov 16, 2026 |
| 10 | Vanguard Fiduciary Trust Co | 476,825 | +66,223 (+16.13%) | 0.61% | $1 M | Nov 13, 2026 |
| 11 | Balyasny Asset Management L.P. | 381,940 | New | 0.49% | $0 M | Nov 16, 2026 |
| 12 | State Street Corp | 324,095 | -7,300 (-2.20%) | 0.42% | $0 M | Nov 12, 2026 |
| 13 | Two Sigma Investments, LP | 321,831 | +274,165 (+575.18%) | 0.41% | $0 M | Nov 16, 2026 |
| 14 | UBS Group AG | 300,156 | -338,543 (-53.01%) | 0.39% | $0 M | Nov 10, 2026 |
| 15 | BNP Paribas Financial Markets | 228,289 | -172 (-0.08%) | 0.29% | $0 M | Nov 12, 2026 |
| 16 | Susquehanna International Group, LLP | 218,495 | +102,357 (+88.13%) | 0.28% | $0 M | Nov 16, 2026 |
| 17 | X-Square Capital, LLC | 205,700 | 0 (0.00%) | 0.26% | $0 M | Nov 10, 2026 |
| 18 | Morgan Stanley | 180,632 | -65,463 (-26.60%) | 0.23% | $0 M | Nov 13, 2026 |
| 19 | Bank of New York Mellon Corp | 161,689 | 0 (0.00%) | 0.21% | $0 M | Nov 5, 2026 |
| 20 | Goldman Sachs Group Inc | 155,143 | +34,316 (+28.40%) | 0.20% | $0 M | Nov 16, 2026 |
| 21 | Northern Trust Corp | 152,875 | 0 (0.00%) | 0.20% | $0 M | Nov 16, 2026 |
| 22 | Millennium Management LLC | 116,375 | -18,142 (-13.49%) | 0.15% | $0 M | Nov 16, 2026 |
| 23 | AlphaCore Capital LLC | 108,426 | -67 (-0.06%) | 0.14% | $0 M | Nov 4, 2026 |
| 24 | Marshall Wace, LLP | 108,099 | -54,115 (-33.36%) | 0.14% | $0 M | Nov 13, 2026 |
| 25 | Jane Street Group, LLC | 78,228 | -529,672 (-87.13%) | 0.10% | $0 M | Nov 12, 2026 |
Show all 75: investors 26 to 75
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Assenagon Asset Management S.A. | 67,231 | -67,231 (-50.00%) | 0.09% | $0 M | Oct 15, 2026 |
| 27 | XTX Topco Ltd | 62,681 | -34,719 (-35.65%) | 0.08% | $0 M | Nov 16, 2026 |
| 28 | Qube Research & Technologies Ltd | 59,359 | -66,191 (-52.72%) | 0.08% | $0 M | Nov 13, 2026 |
| 29 | AQR Capital Management LLC | 53,376 | -292,977 (-84.59%) | 0.07% | $0 M | Nov 16, 2026 |
| 30 | Renaissance Technologies LLC | 51,800 | +37,858 (+271.54%) | 0.07% | $0 M | Nov 12, 2026 |
| 31 | Capstone Investment Advisors, LLC | 51,190 | 0 (0.00%) | 0.07% | $0 M | Nov 16, 2026 |
| 32 | Elkhorn Partners Limited Partnership | 48,000 | 0 (0.00%) | 0.06% | $0 M | Nov 13, 2026 |
| 33 | Creative Planning | 47,287 | -810 (-1.68%) | 0.06% | $0 M | Nov 2, 2026 |
| 34 | Glenview Trust Co | 43,128 | 0 (0.00%) | 0.06% | $0 M | Oct 28, 2026 |
| 35 | HighTower Advisors, LLC | 34,206 | -558 (-1.61%) | 0.04% | $0 M | Nov 10, 2026 |
| 36 | Mariner, LLC | 26,099 | -23,257 (-47.12%) | 0.03% | $0 M | Nov 12, 2026 |
| 37 | Vanguard Global Advisers, LLC | 25,271 | 0 (0.00%) | 0.03% | $0 M | Nov 13, 2026 |
| 38 | Rockefeller Capital Management L.P. | 25,000 | +5,000 (+25.00%) | 0.03% | $0 M | Nov 13, 2026 |
| 39 | Tamar Securities, LLC | 23,795 | 0 (0.00%) | 0.03% | $0 M | Nov 3, 2026 |
| 40 | Royal Bank Of Canada | 23,721 | +11,399 (+92.51%) | 0.03% | $0 M | Nov 16, 2026 |
| 41 | Dimensional Fund Advisors LP | 23,369 | -13,281 (-36.24%) | 0.03% | $0 M | Nov 4, 2026 |
| 42 | Integrity Alliance, LLC. | 22,860 | +10,000 (+77.76%) | 0.03% | $0 M | Oct 29, 2026 |
| 43 | Post Resch Tallon Group Inc. | 22,515 | 0 (0.00%) | 0.03% | $0 M | Oct 9, 2026 |
| 44 | R Squared Ltd | 22,269 | +251 (+1.14%) | 0.03% | $0 M | Nov 6, 2026 |
| 45 | Raymond James Financial Inc | 22,172 | -500 (-2.21%) | 0.03% | $0 M | Nov 12, 2026 |
| 46 | PFG Investments, LLC | 20,501 | 0 (0.00%) | 0.03% | $0 M | Nov 12, 2026 |
| 47 | Baker Ellis Asset Management LLC | 20,000 | 0 (0.00%) | 0.03% | $0 M | Oct 14, 2026 |
| 48 | Proactive Wealth Strategies LLC | 20,000 | 0 (0.00%) | 0.03% | $0 M | Nov 9, 2026 |
| 49 | Brighton Jones LLC | 16,741 | -3,712 (-18.15%) | 0.02% | $0 M | Nov 3, 2026 |
| 50 | Capital Advisors Wealth Management, LLC | 15,525 | 0 (0.00%) | 0.02% | $0 M | Oct 9, 2026 |
| 51 | Wells Fargo & Company/mn | 15,130 | 0 (0.00%) | 0.02% | $0 M | Nov 16, 2026 |
| 52 | MAI Capital Management | 14,576 | -8,797 (-37.64%) | 0.02% | $0 M | Nov 12, 2026 |
| 53 | Gladstone Institutional Advisory LLC | 13,000 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 54 | FMR LLC | 11,611 | +1,818 (+18.56%) | 0.01% | $0 M | Nov 10, 2026 |
| 55 | Ledgewood Wealth Advisors, LLC | 11,190 | 0 (0.00%) | 0.01% | $0 M | Oct 9, 2026 |
| 56 | Security National Bank | 9,767 | 0 (0.00%) | 0.01% | $0 M | Oct 26, 2026 |
| 57 | Trust Co Of Toledo NA /oh/ | 9,000 | 0 (0.00%) | 0.01% | $0 M | Oct 16, 2026 |
| 58 | Golden State Wealth Management, LLC | 7,100 | +50 (+0.71%) | 0.01% | $0 M | Nov 2, 2026 |
| 59 | Federated Hermes, Inc. | 4,232 | -579 (-12.03%) | 0.01% | $0 M | Nov 12, 2026 |
| 60 | IFP Advisors, Inc | 3,859 | +19 (+0.49%) | 0.01% | $0 M | Oct 16, 2026 |
| 61 | US Bancorp \de\ | 3,109 | 0 (0.00%) | 0.00% | $0 M | Nov 5, 2026 |
| 62 | Farther Finance Advisors, LLC | 2,696 | -183 (-6.36%) | 0.00% | $0 M | Oct 8, 2026 |
| 63 | Arax Advisory Partners | 1,993 | -5,688 (-74.05%) | 0.00% | $0 M | Nov 12, 2026 |
| 64 | Jpmorgan Chase & Co | 1,554 | -361 (-18.85%) | 0.00% | $0 M | Nov 12, 2026 |
| 65 | Jones Financial Companies Lllp | 1,000 | +950 (+1900.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 66 | Clearstead Advisors, LLC | 700 | 0 (0.00%) | 0.00% | $0 M | Nov 6, 2026 |
| 67 | Essential Partners LLC | 561 | -1,524 (-73.09%) | 0.00% | $0 M | Oct 14, 2026 |
| 68 | Fortitude Family Office, LLC | 165 | -214 (-56.46%) | 0.00% | $0 M | Oct 14, 2026 |
| 69 | SBI Securities Co., Ltd. | 146 | +1 (+0.69%) | 0.00% | $0 M | Oct 22, 2026 |
| 70 | NewEdge Advisors, LLC | 81 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 71 | Northwestern Mutual Wealth Management Co | 48 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 72 | Parallel Advisors, LLC | 35 | 0 (0.00%) | 0.00% | $0 M | Nov 3, 2026 |
| 73 | SJS Investment Consulting Inc. | 9 | -54 (-85.71%) | 0.00% | $0 M | Oct 26, 2026 |
| 74 | Barclays PLC | 5 | -5,402 (-99.91%) | 0.00% | $0 M | Nov 6, 2026 |
| 75 | ROSS\JOHNSON & Associates LLC | 1 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
Mutual funds holding Cardiff Oncology, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 2.07 M | $3 M | 2.7% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 759,321 | $1 M | 0.98% | <0.01% | +5.8% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 363,388 | $1 M | 0.47% | <0.01% | +1.8% | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 324,898 | $1 M | 0.42% | <0.01% | +6.0% | May 31, 2026 |
| 🇺🇸 Franklin Biotechnology Discovery FundFranklin Advisers, Inc. | 438,961 | $0 M | 0.56% | 0.03% | no change | Jul 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 221,689 | $0 M | 0.28% | 0.02% | +39% | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 114,137 | $0 M | 0.15% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 100,743 | $0 M | 0.13% | <0.01% | +7.6% | May 31, 2026 |
| 🇺🇸 Small Company Growth PortfolioThe Vanguard Group, Inc. | 72,057 | $0 M | 0.09% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 34,646 | $0 M | 0.04% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 46,242 | $0 M | 0.06% | <0.01% | +54% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 28,295 | $0 M | 0.04% | <0.01% | +3.0% | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc. | 25,068 | $0 M | 0.03% | <0.01% | +4.8% | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 35,418 | $0 M | 0.05% | <0.01% | −5.4% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 23,843 | $0 M | 0.03% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 27,727 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 30,591 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC | 16,918 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 22,892 | $0 M | 0.03% | <0.01% | +6.0% | Jul 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 15,011 | $0 M | 0.02% | <0.01% | +25% | Jun 30, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 7,300 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 13,515 | $0 M | 0.02% | <0.01% | +27% | Jul 31, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC | 6,166 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 3,969 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 5,115 | $0 M | <0.01% | <0.01% | +21% | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 7,385 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 7,233 | $0 M | <0.01% | <0.01% | +1.4% | Jul 31, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 2,955 | $0 M | <0.01% | <0.01% | +10% | May 31, 2026 |
| 🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC | 2,310 | $0 M | <0.01% | <0.01% | −40% | May 31, 2026 |
| 🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC | 2,331 | $0 M | <0.01% | <0.01% | −39% | May 31, 2026 |
| 🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC | 1,935 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Morgan Stanley Pathway Small-Mid Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC | 1,563 | $0 M | <0.01% | <0.01% | −5.1% | May 31, 2026 |
| 🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC | 1,854 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 1,791 | $0 M | <0.01% | <0.01% | −66% | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 1,435 | $0 M | <0.01% | <0.01% | +16% | Jun 30, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 542 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 36 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Cardiff Oncology, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Gary W. PaceDirector | Buy | +687,285 | $1.460 | $1.0 M | 2.04 M | Form 4 |
| filed | Mani MohindruChief Executive Officer, Director | Buy | +34,364 | $1.460 | $50 K | 59,067 | Form 4 |
| filed | Mani MohindruChief Executive Officer, Director | Buy | +24,703 | $1.210 | $30 K | 24,703 | Form 4 |
| filed | Gary W. PaceDirector | Buy | +30,000 | $1.220 | $37 K | 1.36 M | Form 4 |
| filed | Gary W. PaceDirector | Buy | +275,000 | $2.450 | $674 K | 1.33 M | Form 4 |
| filed | Gary W. PaceDirector | Buyindirect | +15,000 | $2.450 | $37 K | 1.35 M | Form 4 |
| filed | James E. LevineChief Financial Officer | Buyindirect | +2,400 | $5.000 | $12 K | 67,716 | Form 4 |
| filed | James E. LevineChief Financial Officer | Buyindirect | +2,752 | $5.420 | $15 K | 65,316 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Cardiff Oncology, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-6 reverse split
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q1 2014 | Q1 2014 | $0M |
| Q4 2013 | Q4 2013 | $0M |
| Q3 2013 | Q3 2013 | $0M |
| Q2 2013 | Q2 2013 | $0M |
| Q1 2013 | Q1 2013 | $0M |
| Q4 2012 | Q4 2012 | $0M |
| Q3 2012 | Q3 2012 | $0M |
| Q2 2012 | Q2 2012 | $0M |
Fails to deliver
- : 199 shares at $0.91
- : 41 shares at $0.88
- : 4,982 shares at $0.94
- : 47,210 shares at $0.89
- : 18,173 shares at $0.97
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Cardiff Oncology, Inc. scorecard#
Passes 2 of the 15 checks that could be worked out: strongest in financial health (1 of 3), weakest in growth (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation1 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median1.6×Price to book 1.6× against Biotechnology's median of 2.9×.
- ✗Price to sales below its peers' median128.7×Price to sales 128.7× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-53.6%Free cash flow is -53.6% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 3
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-0.69 vs -0.95Diluted EPS -0.69 in fiscal 2025 against -0.95 the year before (report's currency).
- ✗Net income higher than five years earlier-$46 M-$46 M in fiscal 2025 against -$19 M in 2020.
- ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2025.
Profitability0 of 3
- ✗Profitable in the newest year-$46 MNet income -$46 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-71.5%-71.5% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities3.7×Current ratio 3.67 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-8.91Z-score -8.91 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year40.3%Diluted shares up 40.3% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Cardiff Oncology, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 0.6−13.2%100% | 0.7+40.0%100% | 0.5+26.4%100% | 0.4+7.5%100% | 0.4−1.9%100% | 0.4+49.6%100% | 0.2−35.3%100% | 0.4−25.1%100% | 0.5+32.6%100% | 0.4—100% | |
| Cost of revenue | — | — | — | — | — | — | 0−100%0.0% | 0.6−67.0%158% | 1.8+4.7%358% | 1.7—454% | |
| Research and development | 35−4.1%5958% | 37+12.2%5396% | 33+21.2%6733% | 27+55.7%7021% | 17+54.9%4847% | 11+0.7%3070% | 11+36.7%4563% | 8.2+3.6%2158% | 7.9−47.5%1560% | 15—3938% | |
| Selling, general and administrative | 14+14.0%2399% | 12−4.3%1828% | 13−1.0%2673% | 13+11.3%3415% | 12+44.1%3297% | 8.2r8.2+42.6%2245% | 5.8−28.0%2355% | 8.0−43.8%2116% | 14—2816% | — | |
| Selling and marketing | — | — | — | — | — | — | — | — | 2.7−76.3%541% | 12—3024% | |
| General and administrative | — | — | — | — | — | — | — | — | 11+0.2%2275% | 11—3011% | |
| Operating expenses | 50+0.4%8356% | 49+7.5%7223% | 46+13.9%9406% | 40+37.9%10437% | 29+50.2%8138% | 19r19+14.9%5315% | 17−2.9%6918% | 17−33.2%4608% | 26−35.6%5164% | 41—10635% | |
| Operating income | −49—−8256% | −49—−7123% | −45—−9306% | −40—−10337% | −29—−8038% | −19r−19—−5215% | −17—−6818% | −17—−4508% | −26—−5064% | −40—−10535% | |
| Interest and finance income | 3.1−4.8%523% | 3.3−19.9%477% | 4.1+157%834% | 1.6+499%410% | 0.3+193%73.5% | 0.1r0.1−61.6%24.6% | 0.2+6.7%95.7% | 0.2+48.4%58.0% | 0.1−50.5%29.3% | 0.3—78.4% | |
| Interest expense and finance costs | — | — | — | — | 0−100%0.0% | 0.0r0.0—0.5% | 0−100%0.0% | 0.0−97.5%6.7% | 1.0−38.2%205% | 1.7—439% | |
| Net interest income | — | — | — | — | — | — | — | — | — | −1.4—−361% | |
| Other non-operating income (expense) | 3.1−3.4%524% | 3.2−18.9%471% | 4.0+231%814% | 1.2+112%310% | 0.6—157% | −0.2—−60.4% | — | — | — | — | |
| Income before tax | −46—−7732% | −45—−6652% | — | — | — | — | — | — | — | — | |
| Income tax | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | |
| Net income attributable to shareholders | −46—−7732% | −45—−6652% | −41—−8492% | −39—−10027% | −28—−7881% | −19r−19—−5275% | −16—−6710% | −16—−4351% | −25—−4928% | −39—−10288% | |
| Earnings per share, basic | -0.69—— | -0.95—— | -0.93—— | -0.89—— | -0.73—— | -1.08—— | -2.80—— | -8.26—— | -51.76r-0.72—— | -1.30—— | |
| Earnings per share, diluted | -0.69—— | -0.95—— | -0.93—— | -0.89—— | -0.73—— | -1.08—— | -2.80—— | -8.26—— | -51.76r-0.72—— | -1.37—— | |
| Shares, weighted average (basic) | 67+40.3%— | 48+6.7%— | 45+2.5%— | 44+11.7%— | 39+87.0%— | 21+249%— | 6.0+156%— | 2.3+384%— | 0.5r35−98.4%— | 30—— | |
| Shares, weighted average (diluted) | 67+40.3%— | 48+6.7%— | 45+2.5%— | 44+11.7%— | 39+87.0%— | 21r21+249%— | 6.0+156%— | 2.3+384%— | 0.5r35−98.4%— | 30—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 17−66.1%28.2% | 51+138%53.0% | 22+32.5%26.5% | 16+36.9%14.1% | 12−90.9%8.0% | 131r131+1185%97.2% | 10−11.0%77.9% | 11+39.2%80.8% | 8.2−40.9%67.0% | 14—31.7% | |
| Short-term investments | 41+1.4%66.0% | 40−24.2%41.4% | 53−40.2%65.1% | 89−31.0%76.5% | 129—86.2% | 0—0.0% | — | — | 0−100%0.0% | 24—54.6% | |
| Receivables | 0.2−76.5%0.3% | 0.8+168%0.8% | 0.3−62.6%0.4% | 0.8+44.1%0.7% | 0.5+67.2%0.4% | 0.3r0.3+57.3%0.2% | 0.2+21.3%1.6% | 0.2+118%1.2% | 0.1−23.3%0.6% | 0.1—0.2% | |
| Other current assets | — | — | 2.3−56.1%2.8% | 5.2+10.0%4.5% | 4.8+132%3.2% | 2.1r2.1+115%1.5% | 1.0−16.6%7.3% | 1.1−1.8%8.1% | 1.2+21.9%9.5% | 1.0—2.2% | |
| Current assets | 60−36.7%97.2% | 95+22.8%97.8% | 77−30.4%94.8% | 111−23.8%95.8% | 146+9.6%97.7% | 133r133+1075%99.0% | 11−11.1%86.8% | 13+34.8%90.1% | 9.5−75.7%77.1% | 39—88.6% | |
| Property, plant and equipment | 0.6−35.6%0.9% | 0.9−27.5%0.9% | 1.2−2.4%1.5% | 1.3+232%1.1% | 0.4−38.8%0.3% | 0.6r0.6−28.9%0.5% | 0.9−32.7%6.7% | 1.3−46.2%9.2% | 2.4−36.6%19.8% | 3.8—8.7% | |
| Right-of-use (leased) assets | 0.6−46.2%1.0% | 1.2−31.6%1.2% | 1.7−24.1%2.1% | 2.3−19.5%1.9% | 2.8+715%1.9% | 0.3r0.3−50.8%0.3% | 0.7—5.3% | 0—0.0% | — | — | |
| Total assets | 62−36.3%100% | 97+19.1%100% | 82−29.7%100% | 116−22.3%100% | 150+11.0%100% | 135r135+930%100% | 13−7.7%100% | 14+15.4%100% | 12−72.0%100% | 44—100% | |
| Accounts payable | 8.1+67.7%13.1% | 4.8+145%5.0% | 2.0+0.5%2.4% | 2.0+35.9%1.7% | 1.4+5.3%1.0% | 1.4r1.4+108%1.0% | 0.7−1.3%5.0% | 0.7−19.4%4.7% | 0.8−27.0%6.7% | 1.1—2.6% | |
| Debt due within a year | — | — | — | — | — | — | — | 0−100%0.0% | 1.3−43.6%10.8% | 2.4—5.4% | |
| Current liabilities | 16+22.1%26.5% | 13+28.6%13.8% | 10+33.7%12.8% | 7.8+19.0%6.7% | 6.6+7.2%4.4% | 6.1r6.1+28.0%4.5% | 4.8+63.6%36.5% | 2.9r3.0−25.9%20.6% | 3.9−49.4%32.1% | 7.8—17.7% | |
| Long-term debt | — | — | — | — | — | — | — | — | 0−100%0.0% | 14—32.3% | |
| Lease liabilities (non-current) | 0.1−87.5%0.2% | 0.8−44.2%0.8% | 1.5−28.5%1.8% | 2.0−20.6%1.8% | 2.6+28433%1.7% | 0.0r0.0−99.0%0.0% | 0.9—6.6% | 0—0.0% | — | — | |
| Total liabilities | 16+15.8%26.7% | 14+19.7%14.7% | 12+20.8%14.6% | 9.8+7.9%8.5% | 9.1+38.9%6.1% | 6.6r6.6+13.7%4.9% | 5.8+41.3%44.1% | 4.1−29.3%28.8% | 5.8−76.1%47.0% | 24—55.0% | |
| Retained earnings | −430—−695% | −384—−395% | −340—−416% | −298—−257% | −260—−174% | −231r−231—−172% | −209—−1596% | −192—−1356% | −173—−1409% | −148—−337% | |
| Shareholders' equity | 45−45.3%73.3% | 83+18.9%85.3% | 70−34.4%85.4% | 106−24.3%91.5% | 140+9.6%93.9% | 128r128+1653%95.1% | 7.3r7.3−27.5%55.9% | 10+55.0%71.2% | 6.5−67.1%53.0% | 20—45.0% | |
| Total liabilities and equity | 62−36.3%100% | 97+19.1%100% | 82−29.7%100% | 116−22.3%100% | 150+11.0%100% | 135r135+930%100% | 13−7.7%100% | 14+15.4%100% | 12−72.0%100% | 44—100% | |
| Shares outstanding | 68+2.7%— | 67+48.9%— | 450.0%— | 45+6.5%— | 42+14.1%— | 37r37+328%— | 8.6r8.6+124%— | 3.8r3.8+423%— | 0.7r53−97.6%— | 31—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 0.4−9.9%61.4% | 0.4+1.5%59.2% | 0.4+68.6%81.6% | 0.2−47.7%61.1% | 0.5−3.2%126% | 0.5r0.5−5.7%127% | 0.5−42.5%202% | 0.9−31.1%227% | 1.2+16.6%247% | 1.1—281% | |
| Share-based compensation | 5.7+19.6%960% | 4.8+5.6%697% | 4.5+5.9%924% | 4.3+31.6%1103% | 3.2+83.2%901% | 1.8r1.8+99.4%482% | 0.9−59.3%362% | 2.2−45.8%575% | 4.0−46.5%794% | 7.5—1969% | |
| Cash from operating activities | −38—−6395% | −38—−5519% | −31—−6329% | −34—−8762% | −23—−6418% | −16r−16—−4458% | −13—−5423% | −13—−3489% | −23—−4606% | −31—−8145% | |
| Capital expenditure | −0.0—−7.4% | −0.1—−11.7% | −0.6—−119% | −1.0—−261% | −0.2—−57.1% | −0.2r−0.2—−57.7% | −0.1—−27.6% | −0.0—−1.3% | −0.1—−20.0% | −0.8—−216% | |
| Cash from investing activities | 1.3−90.2%226% | 14−62.1%2010% | 36−5.1%7417% | 38—9883% | −131—−36615% | −0.2r−0.2—−57.7% | −0.1−396%−27.6% | 0.0−99.9%6.0% | 24—4741% | −25—−6517% | |
| Debt issued | — | — | — | — | 0−100%0.0% | 0.3—83.3% | 0—0.0% | — | 0−100%0.0% | 7.8—2048% | |
| Debt repaid | — | — | — | — | — | — | — | 0—0.0% | −15—−2968% | −8.9—−2335% | |
| Shares issued | 0−100%0.0% | 53—7819% | — | 0−100%0.0% | 34−69.6%9523% | 112r112+1174%30684% | 8.8−25.1%3605% | 12r13+0.4%3114% | 12+396%2320% | 2.4r2.3—621% | |
| Cash from financing activities | 2.6−95.2%435% | 54—7874% | 0−100%0.0% | 0.1−99.8%19.4% | 35−74.2%9875% | 137r137+1037%37518% | 12−26.4%4937% | 16—4336% | −6.4−377%−1262% | 2.3—604% | |
| Exchange-rate effect on cash | — | — | — | — | — | — | — | 0−100%0.0% | 0.0—1.5% | −0.0—−1.5% | |
| Change in cash | −34−214%−5734% | 30+462%4365% | 5.3+20.5%1088% | 4.4—1141% | −119−199%−33158% | 121r121—33002% | −1.3−139%−514% | 3.2—853% | — | — | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 0.6+11.6%100% | 0.2+42.5%100% | 0.1−14.0%100% | 0.0−62.4%100% | 0.2*+60.9%100% | 0.1−27.3%100% | 0.1−25.8%100% | 0.1−46.8%100% | 0.2*−3.2%100% | 0.2—100% | 0.2—100% | 0.2—100% | 0.2*—100% | |
| Research and development | 23−43.0%4076% | 5.0−38.6%2941% | 5.9−48.9%5688% | 6.8−35.4%16500% | 5.1*−47.7%2088% | 8.2−15.0%6831% | 12+22.0%9570% | 10+30.8%9612% | 9.7*+25.1%6432% | 9.6—5842% | 9.5—5824% | 8.0—3906% | 7.8*—4976% | |
| Selling, general and administrative | 17+21.4%3092% | 4.4+11.9%2550% | 3.8+14.6%3658% | 6.1+52.6%14941% | 3.0*−0.5%1233% | 3.9+24.7%3248% | 3.3+3.2%2742% | 4.0+28.2%3683% | 3.0*+10.5%1994% | 3.1—1895% | 3.2—1972% | 3.1—1527% | 2.7*—1747% | |
| Operating expenses | 40−26.1%7168% | 9.4−22.4%5491% | 9.7−34.8%9345% | 13−11.0%31441% | 8.1*−36.6%3321% | 12−5.3%10078% | 15+17.2%12312% | 14+30.1%13294% | 13*+21.3%8426% | 13—7737% | 13—7796% | 11—5433% | 10*—6723% | |
| Operating income | −40—−7068% | −9.2—−5391% | −9.6—−9245% | −13—−31341% | −7.8*—−3221% | −12—−9978% | −15—−12212% | −14—−13194% | −13*—−8326% | −13—−7637% | −13—−7696% | −11—−5333% | −10*—−6623% | |
| Interest and finance income | 1.9−43.2%333% | 0.4−49.3%212% | 0.4−54.3%367% | 0.5−46.2%1234% | 0.6*−22.2%252% | 0.7−3.4%597% | 0.8+3.7%690% | 0.9+1.6%863% | 0.8*−21.9%521% | 0.7—449% | 0.8—494% | 0.9—452% | 1.0*—646% | |
| Other non-operating income (expense) | 1.9−43.3%333% | 0.4−49.4%212% | 0.4−54.1%368% | 0.5−46.7%1232% | 0.6*−22.2%251% | 0.7−4.0%597% | 0.8+8.7%689% | 0.9+2.8%870% | 0.8*−21.1%520% | 0.7—452% | 0.8—471% | 0.9—450% | 1.0*—638% | |
| Net income attributable to shareholders | −38—−6735% | −8.9—−5180% | −9.2—−8877% | −12—−30110% | −7.2*—−2970% | −11—−9382% | −14—−11523% | −13—−12325% | −12*—−7806% | −12—−7185% | −12—−7226% | −10—−4883% | −9.3*—−5985% | |
| Earnings per share, basic | — | -0.12—— | -0.14—— | -0.18—— | — | -0.17—— | -0.21—— | -0.20—— | — | -0.25—— | -0.26—— | -0.22—— | — | |
| Earnings per share, diluted | — | -0.12—— | -0.14—— | -0.18—— | — | -0.17—— | -0.21—— | -0.20—— | — | -0.25—— | -0.26—— | -0.22—— | — | |
| Shares, weighted average (basic) | 76+13.9%— | 76+13.9%— | 68+2.8%— | 68+2.7%— | — | 67+42.7%— | 67+48.4%— | 67+48.9%— | — | 47—— | 45—— | 45—— | — | |
| Shares, weighted average (diluted) | 76+13.9%— | 76+13.9%— | 68+2.8%— | 68+2.7%— | — | 67+42.7%— | 67+48.4%— | 67+48.9%— | — | 47—— | 45—— | 45—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 12—33.1% | 12+19.0%33.1% | 9.2−14.7%24.6% | 8.5−64.5%17.4% | 17−66.1%28.2% | 10−22.3%15.9% | 11−57.7%14.2% | 24+29.1%28.4% | 51+138%53.0% | 13—20.7% | 26—38.6% | 19—25.2% | 22—26.5% | |
| Short-term investments | 22—59.7% | 22−56.9%59.7% | 25−57.9%67.8% | 38−32.8%76.3% | 41+1.4%66.0% | 50+13.1%79.1% | 60+72.8%79.4% | 56+15.0%65.8% | 40−24.2%41.4% | 45—71.0% | 35—52.7% | 49—65.5% | 53—65.1% | |
| Receivables | 0.1—0.2% | 0.1−64.6%0.2% | 0.2−64.1%0.5% | 0.2−52.8%0.4% | 0.2−76.5%0.3% | 0.3−58.9%0.4% | 0.5+16.6%0.7% | 0.4+3.1%0.5% | 0.8+168%0.8% | 0.6—1.0% | 0.5—0.7% | 0.4—0.5% | 0.3—0.4% | |
| Other current assets | — | — | — | — | — | — | — | — | — | — | — | — | 2.3—2.8% | |
| Current assets | 35—96.2% | 35−43.3%96.2% | 36−51.7%95.3% | 47−42.8%96.3% | 60−36.7%97.2% | 62+4.2%96.9% | 74+18.4%97.3% | 83+18.2%97.5% | 95+22.8%97.8% | 59—94.3% | 62—94.2% | 70—94.5% | 77—94.8% | |
| Property, plant and equipment | 0.4—1.0% | 0.4−45.3%1.0% | 0.5−32.4%1.2% | 0.5−39.0%1.0% | 0.6−35.6%0.9% | 0.7−32.9%1.0% | 0.7r0.7−39.2%0.9% | 0.8−32.9%0.9% | 0.9−27.5%0.9% | 1.0—1.6% | 1.1—1.7% | 1.2—1.6% | 1.2—1.5% | |
| Right-of-use (leased) assets | 0.2—0.6% | 0.2−70.5%0.6% | 0.4−60.0%1.0% | 0.5−52.1%1.0% | 0.6−46.2%1.0% | 0.8−41.4%1.2% | 0.9−37.5%1.2% | 1.0−34.3%1.2% | 1.2−31.6%1.2% | 1.3—2.1% | 1.4—2.2% | 1.6—2.1% | 1.7—2.1% | |
| Total assets | 36—100% | 36−42.9%100% | 37−50.7%100% | 49−42.0%100% | 62−36.3%100% | 64+1.4%100% | 76+14.7%100% | 85+14.5%100% | 97+19.1%100% | 63—100% | 66—100% | 74—100% | 82—100% | |
| Accounts payable | 0.7—1.9% | 0.7−71.6%1.9% | 4.0−33.7%10.7% | 5.5+51.0%11.1% | 8.1+67.7%13.1% | 2.4−47.4%3.8% | 6.0+17.7%7.9% | 3.6−30.1%4.3% | 4.8+145%5.0% | 4.6—7.4% | 5.1—7.7% | 5.2—7.0% | 2.0—2.4% | |
| Current liabilities | 8.3—22.8% | 8.3−43.5%22.8% | 11−35.2%28.9% | 14+8.8%29.4% | 16+22.1%26.5% | 15+17.4%23.1% | 17+33.1%22.0% | 13+12.2%15.7% | 13+28.6%13.8% | 13—19.9% | 13—19.0% | 12—16.0% | 10—12.8% | |
| Lease liabilities (non-current) | 0—0.0% | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 0.1−87.5%0.2% | 0.3−71.0%0.4% | 0.5−59.3%0.6% | 0.6−50.8%0.8% | 0.8−44.2%0.8% | 1.0—1.6% | 1.1—1.7% | 1.3—1.8% | 1.5—1.8% | |
| Total liabilities | 8.3—22.8% | 8.3−44.5%22.8% | 11−37.0%28.9% | 14+3.8%29.4% | 16+15.8%26.7% | 15+11.0%23.5% | 17+25.4%22.6% | 14+6.0%16.4% | 14+19.7%14.7% | 14—21.5% | 14—20.7% | 13—17.8% | 12—14.6% | |
| Retained earnings | −460—−1265% | −460—−1265% | −452—−1210% | −442—−900% | −430—−695% | −423—−663% | −412—−543% | −398—−469% | −384—−395% | −372—−592% | −361—−546% | −349—−471% | −340—−416% | |
| Shareholders' equity | 28—77.2% | 28−42.4%77.2% | 27−54.7%71.1% | 35−51.0%70.6% | 45−45.3%73.3% | 49−1.2%76.5% | 59+11.9%77.4% | 71+16.4%83.6% | 83+18.9%85.3% | 49—78.5% | 52—79.3% | 61—82.2% | 70—85.4% | |
| Total liabilities and equity | 36—100% | 36−42.9%100% | 37−50.7%100% | 49−42.0%100% | 62−36.3%100% | 64+1.4%100% | 76+14.7%100% | 85+14.5%100% | 97+19.1%100% | 63—100% | 66—100% | 74—100% | 82—100% | |
| Shares outstanding | 78—— | 78+15.9%— | 69+3.0%— | 68+2.8%— | 68+2.7%— | 67+37.7%— | 67+45.9%— | 67+48.8%— | 67+48.9%— | 49—— | 46—— | 45—— | 45—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.4−5.9%62.6% | 0.1*−1.1%51.5% | 0.1*−7.4%83.7% | 0.1−6.5%212% | 0.1*−8.3%36.2% | 0.1*−11.9%74.2% | 0.1*−10.5%77.7% | 0.1−8.8%85.3% | 0.1*−6.8%63.6% | 0.1*—61.2% | 0.1*—64.4% | 0.1—49.8% | 0.1*—66.0% | |
| Share-based compensation | 5.2−8.0%927% | 1.3−3.0%785% | 0.9−45.3%885% | 1.7+21.6%4049% | 1.3*+4.7%519% | 1.4+10.5%1153% | 1.7+42.7%1391% | 1.4+21.4%1252% | 1.2*+32.5%797% | 1.3—759% | 1.2—723% | 1.1—548% | 0.9*—583% | |
| Cash from operating activities | −40—−7137% | −9.9*—−5774% | −12*—−11313% | −12—−29971% | −6.0*—−2456% | −11*—−9028% | −8.3*—−6883% | −13—−11738% | −10*—−6799% | −10*—−6337% | −9.2*—−5663% | −7.7—−3776% | −7.1*—−4576% | |
| Capital expenditure | — | −0.0*—−2.3% | — | — | 0*—0.0% | −0.0*—−15.0% | — | — | 0*—0.0% | 0*—0.0% | 0*—0.0% | −0.1—−39.0% | −0.0*—−5.1% | |
| Cash from investing activities | 30—5346% | 3.6*−64.5%2109% | 12*—11797% | 3.3—7944% | 11*+138%4423% | 10*—8467% | −5.0*−136%−4118% | −15−415%−13380% | 4.5*−66.7%2987% | −9.4*—−5718% | 14*—8598% | 4.6—2261% | 14*—8693% | |
| Shares issued | — | — | — | — | — | — | — | — | 44*—29255% | 7.4—4485% | — | — | — | |
| Cash from financing activities | 12−73.0%2135% | 9.1*+36420%5339% | 0.1*—143% | 0.1+3400%256% | 2.6*−94.2%1051% | 0.0*−99.7%20.8% | 0*−100%0.0% | 0.0−97.2%2.8% | 44*—29264% | 7.4*—4501% | 2.1*—1263% | 0.1—52.2% | 0*—0.0% | |
| Change in cash | 1.9—344% | 2.9*—1674% | 0.7*—628% | −8.9—−21771% | 7.3*−80.9%3019% | −0.6*—−541% | −13*−295%−11001% | −27—−25115% | 38*+498%25452% | −12*—−7553% | 6.8*—4198% | −3.0—−1462% | 6.4*—4117% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Cardiff Oncology, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Acquisition or sale completed 1 · Directors and officers 5 · Material agreement 5 · Bylaws or fiscal year changed 2 · Shareholder vote 3 · Results announced 9
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Directors and officersBylaws or fiscal year changed | 8-K | |
| Shareholder vote | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Shareholder vote | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officersMaterial agreement | 8-K | |
| Acquisition or sale completed | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
2 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jun 2020 | $14 M | Private placement after listing | $10 to $50 million | 3 | equity, options | SEC |
| May 2020 | $3 M | Private placement after listing | $2 to $10 million | 1 | equity, options | SEC |
| Mar 2020 | $2 M | Private placement after listing | $2 to $10 million | 1 | equity, options | SEC |
| Oct 2019 | $5 M | Private placement after listing | $2 to $10 million | 2 | equity, options | SEC |
| Aug 2019 | $2 M | Private placement after listing | Under $2 million | 1 | equity, options | SEC |
| May 2019 | $2 M | Private placement after listing | Under $2 million | 1 | equity, options | SEC |
| Apr 2019 | $2 M | Private placement after listing | Under $2 million | 1 | equity, options | SEC |
| Nov 2012 | $4 M | No. 2 | $2 to $10 million | 8 | equity, options | SEC |
| Jun 2009 | $7 M | No. 1 | $2 to $10 million | 40 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How Cardiff Oncology, Inc. compares in Biotechnology
- Market cap$71 M · higher than 31% of 726
- Revenue$1 M · higher than 22% of 647
- Revenue growth-13.2% · higher than 32% of 438
- Price / sales128.7× · lower than 8% of 339
- Price / book1.6× · lower than 65% of 534
- FCF yield-53.6% · higher than 22% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Cardiff Oncology, Inc.🇺🇸 | $71 M | — | — | -13.2% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Cardiff Oncology, Inc.? Verify and update this profile — free
Show Cardiff Oncology, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.